<DOC>
	<DOCNO>NCT02045654</DOCNO>
	<brief_summary>To assess efficacy decitabine identify predictor response decitabine therapy .</brief_summary>
	<brief_title>Platelet Response During Second Cycle Decitabine Can Predict Response Survival Myelodysplastic Syndrome</brief_title>
	<detailed_description>- Histologically confirm Myelodysplastic syndrome Diagnosed MDS ( de novo secondary ) base World Health Organization ( WHO ) classification - Survival response Analysis - Response rate - Overall survival - Leukemia free survival</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>Histologically confirm Myelodysplastic syndrome Diagnosed MDS ( de novo secondary ) base World Health Organization ( WHO ) classification</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>